Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Minimally Invasive Treatment Of Lung Cancer Market Expected To Reach $5.21 Billion By 2030 At 9.2% CAGR
The market for minimally invasive lung cancer treatments has experienced robust expansion recently, projecting a significant increase from its 2025 valuation of $3.35 billion to $3.67 billion by 2026, reflecting a compound annual growth rate of 9.5%. This historical growth trajectory is underpinned by several key factors, including a rise in lung cancer diagnoses, the proliferation of specialized cancer treatment facilities, advancements in interventional radiology, a broader selection of less invasive therapeutic choices, and increasing endorsement of ablation techniques within the medical community.
The market for minimally invasive treatments for lung cancer is poised for considerable expansion in the upcoming years, projecting a reach of $5.21 billion by 2030 with a compound annual growth rate of 9.2%. This anticipated growth stems from amplified investments in precise cancer care, a heightened embrace of robotic and AI-driven oncology interventions, the broadening of early-stage lung cancer detection initiatives, an escalating demand for outpatient cancer therapies, and a more pronounced emphasis on individualized treatment strategies. Key developments expected during this forecast period encompass a greater utilization of image-guided tumor ablation methods, a surge in the application of minimally invasive embolization techniques, increased incorporation of robotic assistance within oncology services, the development of advanced precision oncology treatment platforms, and a heightened priority on minimizing treatment-associated complications.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27349&type=smp
Minimally Invasive Treatment Of Lung Cancer Market Industry Drivers: What Is Driving Revenue Growth?
The rising incidence of lung cancer is anticipated to be a primary catalyst for the expansion of the minimally invasive lung cancer treatment market. Lung cancer, which commences in the lungs, is marked by the abnormal proliferation of cells, a condition exacerbated by the escalating rates of tobacco consumption, thereby heightening the probability of malignant growths and tumor development. Minimally invasive methods offer significant advantages to individuals battling lung cancer by precisely aiming at and eradicating or destroying tumors via minuscule incisions or image-guided instruments. This approach translates to shorter recovery periods, preservation of healthy lung tissue, diminished complication risks, and a quicker return to daily routines for patients. Illustrating this trend, the American Cancer Society, a U.S. non-profit, projected in January 2023 that an estimated 238,340 new cases of lung cancer—117,550 among males and 120,790 among females—would be identified in 2023, with the disease sadly expected to cause approximately 127,070 fatalities. Consequently, the growing burden of lung cancer is directly fueling the growth trajectory of the minimally invasive treatment segment within this market.
Minimally Invasive Treatment Of Lung Cancer Market Segmentation Trends And Revenue Drivers
The minimally invasive treatment of lung cancer market covered in this report is segmented –
1) By Type: Lung Tumor Ablation, Lung Tumor Embolization
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By Age Group: Under 30 Years, 31 To 45 Years, 46 To 60 Years
4) By End-User: Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Research Institutions
Subsegments:
1) By Lung Tumor Ablation: Radiofrequency Ablation, Microwave Ablation, Cryoablation, Laser Ablation
2) By Lung Tumor Embolization: Bronchial Artery Embolization, Pulmonary Artery Embolization, Chemoembolization, Radioembolization
#Minimally Invasive Treatment Of Lung Cancer Market Growth Trends: What Is Influencing The Future Outlook?
The major players within the market for minimally invasive lung cancer treatments are allocating resources towards pioneering advancements, including microwave ablation systems and navigation-guided biopsy tools. These developments are driven by an increasing preference for lung-preserving interventions, expedited diagnostic processes, reduced hospitalization periods, and alternative treatments for individuals unsuitable for conventional surgery. Microwave ablation (MWA) technology functions by directing high-frequency electromagnetic energy via a probe, effectively heating and destroying cancerous tissue to create well-defined, spherical ablation zones. This method offers quicker treatment durations and mitigates the heat-sink effect when contrasted with radiofrequency ablation. Demonstrating this trend, Creo Medical Group plc, a prominent UK-based developer of minimally invasive surgical endoscopy devices, launched its MicroBlate Flex soft-tissue microwave ablation system in January 2025, subsequently initiating clinical trials for lung ailments. The MicroBlate Flex comprises a microwave generator and a pliable ablation applicator engineered for diverse soft-tissue applications. It operates by emitting high-frequency microwave energy at the applicator’s extremity, thereby generating localized thermal fields that eradicate malignant cells. Key attributes of this system encompass a high-frequency power output for optimal energy delivery, a flexible applicator design to access challenging anatomical regions, and adaptability for both endoscopic and percutaneous procedures, making it suitable for treating small pulmonary nodules, metastatic lung lesions, and patients unable to undergo lobectomy. From a clinical standpoint, these advancements result in abbreviated procedure durations, a decreased reliance on general anesthesia, the potential for same-day discharge, and a broader array of therapeutic possibilities compared to open surgical procedures or stereotactic radiation therapy.
Minimally Invasive Treatment Of Lung Cancer Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the minimally invasive treatment of lung cancer market are Johnson & Johnson, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Intuitive Surgical Inc., Accuray Incorporated, Richard Wolf GmbH, AngioDynamics Inc., CMR Surgical Ltd., Guangzhou Geyi Medical Instrument Co. Ltd., Quantum Surgical SA, Scanlan International Inc., RZ Medizintechnik GmbH & Co. KG, August Reuchlen GmbH, SBH Surgical GmbH & Co. KG, Geister Medizintechnik GmbH, Cook Medical Incorporated, Terumo Corporation, Merit Medical Systems Inc., Sirtex Medical Limited
Access The Complete Minimally Invasive Treatment Of Lung Cancer Market Report:
Minimally Invasive Treatment Of Lung Cancer Market Regional Outlook: Where Are The Largest Opportunities Located?
North Americawas the largest region in the minimally invasive treatment of lung cancer market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the minimally invasive treatment of lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
